OPKO Health (NASDAQ:OPK) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of OPKO Health (NASDAQ:OPK) from a sell rating to a hold rating in a research note released on Sunday morning.

OPK has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research report on Wednesday, October 8th. Barrington Research restated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research note on Thursday, October 30th. Jefferies Financial Group reiterated a “hold” rating and issued a $1.60 target price (down previously from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. Finally, JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a research note on Thursday, November 20th. They set a “neutral” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, OPKO Health currently has a consensus rating of “Hold” and a consensus target price of $2.28.

OPKO Health Price Performance

OPK stock opened at $1.31 on Friday. The stock has a market cap of $1.01 billion, a PE ratio of -5.24 and a beta of 1.34. The firm’s 50-day simple moving average is $1.38 and its 200 day simple moving average is $1.38. OPKO Health has a fifty-two week low of $1.11 and a fifty-two week high of $2.04. The company has a quick ratio of 3.32, a current ratio of 3.70 and a debt-to-equity ratio of 0.25.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.05. The company had revenue of $151.67 million for the quarter, compared to analyst estimates of $165.74 million. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.67%. OPKO Health’s revenue was down 12.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.03 earnings per share. As a group, sell-side analysts predict that OPKO Health will post -0.25 EPS for the current year.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 580,000 shares of the company’s stock in a transaction on Friday, November 21st. The shares were purchased at an average cost of $1.33 per share, for a total transaction of $771,400.00. Following the completion of the transaction, the chief executive officer owned 216,706,448 shares in the company, valued at $288,219,575.84. The trade was a 0.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders bought 1,843,300 shares of company stock worth $2,421,491 over the last quarter. 49.69% of the stock is owned by insiders.

Hedge Funds Weigh In On OPKO Health

Several hedge funds have recently made changes to their positions in OPK. Brighton Jones LLC lifted its stake in OPKO Health by 29.1% during the second quarter. Brighton Jones LLC now owns 38,916 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 8,775 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of OPKO Health by 4.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 198,148 shares of the biotechnology company’s stock valued at $262,000 after buying an additional 8,954 shares in the last quarter. 360 Financial Inc. lifted its position in shares of OPKO Health by 12.0% during the 2nd quarter. 360 Financial Inc. now owns 88,800 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 9,500 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of OPKO Health by 11.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 138,643 shares of the biotechnology company’s stock worth $183,000 after acquiring an additional 13,912 shares in the last quarter. Finally, Caprock Group LLC bought a new stake in shares of OPKO Health during the 3rd quarter worth $26,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.